journal article·2024-06Open access

Alleviating Recombinant Tissue Plasminogen Activator‐induced Hemorrhagic Transformation in Ischemic Stroke via Targeted Delivery of a Ferroptosis Inhibitor

Yan‐Qin Geng, Li‐Na Qiu, Yuan‐Qiu Cheng, Juan‐Juan Li, Yi‐Lin Ma, Cheng‐Cheng Zhao, Ying Cai, Xue‐Bin Zhang, Jieli Chen, Yu‐Chen Pan, Ke‐Rang Wang, Xiu‐Hua Yao, Dong‐Sheng Guo, Jia‐Ling Wu

Advanced Science· Volume 11· Issue 24

Abstract

Abstract Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) is the primary treatment for ischemic stroke. However, rtPA treatment can substantially increase blood‐brain barrier (BBB) permeability and susceptibility to hemorrhagic transformation. Herein, the mechanism underlying the side effects of rtPA treatment is investigated and demonstrated that ferroptosis plays an important role. The ferroptosis inhibitor, liproxstatin‐1 (Lip) is proposed to alleviate the side effects. A well‐designed macrocyclic carrier, glucose‐modified azocalix[4]arene (GluAC4A), is prepared to deliver Lip to the ischemic site. GluAC4A bound tightly to Lip and markedly improved its solubility. Glucose, modified at the upper rim of GluAC4A, imparts BBB targeting to the drug delivery system owing to the presence of glucose transporter 1 on the BBB surface. The responsiveness of GluAC4A to hypoxia due to the presence of azo groups enabled the targeted release of Lip at the ischemic site. GluAC4A successfully improved drug accumulation in the brain, and Lip@GluAC4A significantly reduced ferroptosis, BBB leakage, and neurological deficits induced by rtPA in vivo. These findings deepen the understanding of the side effects of rtPA treatment and provide a novel strategy for their effective mitigation, which is of great significance for the treatment and prognosis of patients with ischemic stroke.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Ferroptosis and cancer prognosis · Cancer-related molecular mechanisms research · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Medicine Nankai University Tianjin 300071 China

Tianjin Huanhu Hospital Tianjin 300350 China

Department of Neurology Tianjin Huanhu Hospital Tianjin 300350 China

Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases Tianjin Neurosurgical Institute Tianjin Huanhu Hospital Tianjin 300350 China

College of Chemistry State Key Laboratory of Elemento‐Organic Chemistry Key Laboratory of Functional Polymer Materials (Ministry of Education) Frontiers Science Center for New Organic Matter Collaborative Innovation Center of Chemical Science and Engineering (Tianjin) Nankai University Tianjin 300071 China

College of Chemistry and Environmental Science Key Laboratory of Medicinal Chemistry and Molecular Diagnosis (Ministry of Education) Key Laboratory of Chemical Biology of Hebei Province Hebei University Baoding 071002 China

Clinical College of Neurology Neurosurgery and Neurorehabilitation Tianjin Medical University Tianjin 300071 China

Department of Pathology Tianjin Huanhu Hospital Tianjin 300350 China

Xinjiang Key Laboratory of Novel Functional Materials Chemistry College of Chemistry and Environmental Sciences Kashi University Kashi 844000 China

Funding

National Natural Science Foundation of China · National Key Clinical Specialty Discipline Construction Program of China

References (55)

Show source-provided references
1. 10.5551/jat.RV1600610.5551/jat.RV16006 ↗
2. 10.1161/CIRCRESAHA.121.31994810.1161/CIRCRESAHA.121.319948 ↗
3. 10.1097/WCO.000000000000100410.1097/WCO.0000000000001004 ↗
4. 10.1016/S1474-4422(22)00519-110.1016/S1474-4422(22)00519-1 ↗
5. 10.1161/STROKEAHA.118.02068310.1161/STROKEAHA.118.020683 ↗
6. 10.1136/jnnp-2019-32190410.1136/jnnp-2019-321904 ↗
7. 10.1016/j.actbio.2022.10.02210.1016/j.actbio.2022.10.022 ↗
8. 10.1161/01.STR.0000016323.13456.E510.1161/01.STR.0000016323.13456.E5 ↗
9. 10.1021/acsnano.9b0582110.1021/acsnano.9b05821 ↗
10. 10.1016/j.jconrel.2020.05.00810.1016/j.jconrel.2020.05.008 ↗
11. 10.1016/j.cell.2019.03.03210.1016/j.cell.2019.03.032 ↗
12. 10.1016/j.drudis.2020.12.02010.1016/j.drudis.2020.12.020 ↗
13. 10.1038/ncb306410.1038/ncb3064 ↗
14. 10.1002/advs.20220469710.1002/advs.202204697 ↗
15. 10.1038/s41467-020-20154-810.1038/s41467-020-20154-8 ↗
16. 10.1111/jpi.1270410.1111/jpi.12704 ↗
17. 10.1038/mp.2017.17110.1038/mp.2017.171 ↗
18. 10.3389/fncel.2021.63235410.3389/fncel.2021.632354 ↗
19. 10.1038/s41418-019-0299-410.1038/s41418-019-0299-4 ↗
20. 10.1002/ejp.173710.1002/ejp.1737 ↗
21. 10.1016/j.jneuroim.2023.57802110.1016/j.jneuroim.2023.578021 ↗
22. 10.1093/immadv/ltad01210.1093/immadv/ltad012 ↗
23. 10.1038/mtm.2014.2810.1038/mtm.2014.28 ↗
24. 10.1002/anie.20170900210.1002/anie.201709002 ↗
25. 10.1039/C9CS00622B10.1039/C9CS00622B ↗
26. 10.1039/C7CS00391A10.1039/C7CS00391A ↗
27. 10.1021/jacsau.3c0027310.1021/jacsau.3c00273 ↗
28. 10.1021/accountsmr.3c0013010.1021/accountsmr.3c00130 ↗
29. 10.1002/adma.20220376510.1002/adma.202203765 ↗
30. 10.1002/adma.20200771910.1002/adma.202007719 ↗
31. 10.1002/adma.20190843510.1002/adma.201908435 ↗
32. 10.1021/cr500392w10.1021/cr500392w ↗
33. 10.31635/ccschem.022.20220185910.31635/ccschem.022.202201859 ↗
34. 10.1002/anie.19950713110.1002/anie.199507131 ↗
35. 10.1038/s41467-022-33920-710.1038/s41467-022-33920-7 ↗
36. 10.1016/j.jhep.2023.03.01610.1016/j.jhep.2023.03.016 ↗
37. 10.1038/s41556-023-01133-910.1038/s41556-023-01133-9 ↗
38. 10.1021/acscentsci.0c0159210.1021/acscentsci.0c01592 ↗
39. 10.1016/j.bbi.2021.01.00310.1016/j.bbi.2021.01.003 ↗
40. 10.1016/j.cell.2013.12.01010.1016/j.cell.2013.12.010 ↗
41. 10.1161/CIRCRESAHA.120.31650910.1161/CIRCRESAHA.120.316509 ↗
42. 10.3390/biom1109136110.3390/biom11091361 ↗
43. 10.1007/s13238-020-00789-510.1007/s13238-020-00789-5 ↗
44. 10.1038/mp.2016.19610.1038/mp.2016.196 ↗
45. 10.1021/acs.nanolett.3c0236210.1021/acs.nanolett.3c02362 ↗
46. 10.1002/anie.20221357810.1002/anie.202213578 ↗
47. 10.1002/sstr.20220006710.1002/sstr.202200067 ↗
48. 10.1002/anie.20221357810.1002/anie.202213578 ↗
49. 10.1002/anie.20221357210.1002/anie.202213572 ↗
50. 10.1039/C8CS00304A10.1039/C8CS00304A ↗
51. 10.1007/s11426‐023‐1857‐210.1007/s11426‐023‐1857‐2 ↗
52. 10.1161/CIRCRESAHA.119.31646310.1161/CIRCRESAHA.119.316463 ↗
53. 10.1016/j.redox.2020.10179210.1016/j.redox.2020.101792 ↗
54. 10.1016/j.intimp.2022.10877010.1016/j.intimp.2022.108770 ↗
55. 10.4103/1673-5374.30303710.4103/1673-5374.303037 ↗